Exabis Library
Welcome to the e-CCO Library!
P362: Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P362: Longitudinal antibody response to SARS-CoV-2 infection and antibody responses to COVID-19 vaccination in Inflammatory Bowel Disease patients receiving biologics
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P362: Magnetic resonance healing predicts long-term outcomes in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P362: Six-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P362: Systematic review: Oncological outcomes of patients with Inflammatory Bowel Disease undergoing segmental colonic resections for colorectal cancer and dysplasia
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P363 Moderate endurance and muscle training are safe to perform for patients with quiescent or mild active Crohn’s disease and increases their strength
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P363: Are clinical decision support tools for vedolizumab and ustekinumab in biologic naïve patients with Crohn’s disease drug-specific?
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P363: Depression and anxiety in Clostridioides difficile infection compared with inflammatory bowel disease during the Covid-19 pandemic
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P363: Discontinuation of 5-aminosalicylates after starting biologic therapy in patients with ulcerative colitis is not associated with adverse outcomes
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P363: Efficacy and safety of golimumab in patients with ulcerative colitis: a prospective multicentre study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P363: Locally injected allogeneic bone marrow-derived mesenchymal stromal cells for the treatment of refractory proctitis: clinical results of a phase IIa trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P363: The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P363: The minimal invasive surgery in combination with negative pressure wound therapy for perianal fistulas in Crohn’s colitis lead to the fast introduction of the biological treatment and improve the results
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P364 New insights into the molecular mechanisms of thalidomide in paediatric inflammatory bowel disease patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P364: A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P364: Comparison of two treatment strategies in IBD: Biosimilar adalimumab (CinnoRA®) in monotherapy and in combination with azathioprine
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P364: Patient reported outcomes, partial MAYO score and SCCAI are equally accurate in predicting mucosal healing in UC: final results form a prospective study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P364: Presence of malnutrition adversely affects short-term clinical outcomes in a sample of patients with Crohn's disease (CD)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P364: Stopping azathioprine in monotherapy after very prolonged remission in inflammatory bowel disease patients: Novel relapse risk factors
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P364: The efficacy of initial treatment with infliximab without previous conventional therapy in patients with moderate-to-severe ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM